How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Vascular Bypass Market
- By Bypass Type: Coronary Artery Bypass Grafting (CABG), Peripheral Artery Bypass, Carotid Artery Bypass, Renal Artery Bypass, Aortic Bypass
- By Graft Material: Autologous Vein Grafts, Synthetic Grafts (ePTFE, Dacron), Biological Grafts, Allografts, Xenografts
- By Procedure Approach: Open Surgery, Minimally Invasive Surgery, Endoscopic Vein Harvesting, Robotic-Assisted Surgery
- By Indication: Coronary Artery Disease, Peripheral Artery Disease, Carotid Artery Disease, Renal Artery Stenosis
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Coronary Artery Bypass Grafting (CABG) leads By Bypass Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Vascular Bypass Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Bypass Type 5
Graft Material 5
Procedure Approach 4
Indication 4
End User 3
Companies profiled
Medtronic plc
Terumo Corporation
W. L. Gore & Associates Inc.
Getinge AB
B. Braun Melsungen AG
Cook Medical
C.R. Bard
Inc. (now part of BD)
Maquet (Getinge Group)
LeMaitre Vascular Inc.
Vascutek Ltd (Terumo)
Sorin Group (LivaNova)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →W. L. Gore & Associates Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Getinge AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →C.R. Bard
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Inc. (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Maquet (Getinge Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →LeMaitre Vascular Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vascutek Ltd (Terumo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sorin Group (LivaNova)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →CryoLife Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Atrium Medical Corporation (Maquet)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Vascutek Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Aesculap (B. Braun)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,053M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Coronary Artery Bypass Grafting (CABG)38.5
- Peripheral Artery Bypass19.0
- Carotid Artery Bypass14.6
- Renal Artery Bypass9.3
- Aortic Bypass18.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$565.9M → $1,287M · 10.8%
Europe$394.4M → $953.3M · 11.7%
Asia Pacific$360.1M → $804.0M · 10.6%
Latin America$222.9M → $569.4M · 12.4%
Middle East and Africa$171.5M → $373.5M · 10.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.292026
11.312027
11.322028
11.342029
11.362030
11.362031
11.372032
11.392033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc11.9
- Terumo Corporation25.7
- W. L. Gore & Associates Inc.4.9
- Getinge AB11.7
- B. Braun Melsungen AG6.5
- Cook Medical11.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Bypass Type11.3%
Graft Material26.2%
Procedure Approach17.3%
Indication20.3%
End User24.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe23.9
- Asia Pacific20.2
- Latin America14.3
- Middle East and Africa9.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 88 | 84 | 75 | 97 | 97 | 92 | 89 |
| Terumo Corporation | 82 | 74 | 90 | 76 | 72 | 74 | 78 |
| W. L. Gore & Associates Inc. | 67 | 73 | 69 | 82 | 80 | 71 | 74 |
| Getinge AB | 75 | 66 | 73 | 61 | 57 | 74 | 68 |
| B. Braun Melsungen AG | 65 | 54 | 67 | 77 | 65 | 65 | 66 |
| Cook Medical | 63 | 59 | 47 | 62 | 65 | 62 | 60 |
| C.R. Bard | 51 | 65 | 61 | 48 | 65 | 43 | 56 |
| Inc. (now part of BD) | 45 | 46 | 42 | 56 | 56 | 54 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Terumo Corporation
- W. L. Gore & Associates Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Terumo Corporation | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| W. L. Gore & Associates Inc. | − | − | ◐ | ◐ | ✓ | ◐ |
| Getinge AB | ✓ | ◐ | ◐ | − | ◐ | ✓ |
| B. Braun Melsungen AG | − | ◐ | ◐ | ✓ | ◐ | ◐ |
| Cook Medical | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| C.R. Bard | − | − | ✓ | ◐ | ◐ | − |
| Inc. (now part of BD) | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc89
2Terumo Corporation78
3W. L. Gore & Associates Inc.74
4Getinge AB68
5B. Braun Melsungen AG66
6Cook Medical60
7C.R. Bard56
8Inc. (now part of BD)50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcTerumo Corporation
Challenger2
Strong scale, closing on the leaders.
W. L. Gore & Associates Inc.Getinge AB
Contender2
Focused players with pockets of strength.
B. Braun Melsungen AGCook Medical
Niche2
Specialists in a single segment or region.
C.R. BardInc. (now part of BD)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Bypass Type in North America, then scale across Vascular Bypass Market — a $682M beachhead inside a $11.4B market.
Beachhead (SOM)$682Mobtainable near-term
Serviceable (SAM)$4.43Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Coronary Artery Bypass Grafting (CABG)
Best fit — highest urgency & budget in Bypass Type.
Economic buyer78 fit
Peripheral Artery Bypass
Strong fit — clear ROI and a fast path to value.
End user70 fit
Carotid Artery Bypass
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Bypass Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Graft Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Procedure Approach
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Bypass Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Vascular Bypass Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation13%
Closed-won6%
$13.8KCAC
$53KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Vascular Bypass Market is a durable-growth opportunity — $3.56B by 2033, compounding at 6.7%.
TAM · 2025$2.12Btoday
TAM · 2033$3.56Bforecast
CAGR6.7%2027–2033
Cumulative$25.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.56BTotal addressable market
SAM$1.36BServiceable available market
SOM$234MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.7% CAGR
Demand compounds through 2033, outpacing GDP across Bypass Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Bypass Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.56BLarge & growingTAM by 2033 at 6.7% CAGR
$1.36BServiceable nowreachable with today’s model
$234MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.78BBear4.4% CAGR
$3.56BBase6.7% CAGR
$4.56BBull8.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Graft Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Vascular Bypass Market — a $10.1B market by 2033. Plan: grow share from 5.8% to 11.0%.
Market size · 2033$10.1Btotal addressable
Market CAGR11.3%2027–2033
Target share11.0%from 5.8% today
Revenue ambition$1.11Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 11.0% | On track |
| Revenue | $590M | $1.11B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.0% | 43.8% | On track |
| Customer retention | 87.4% | 96.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Bypass Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Graft Material capability
A defensible second engine — invest in Graft Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Bypass Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Graft Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $112M capacity & capability investment
- Greenlight bolt-on M&A in Graft Material
- Authorise North America expansion plan
- Fund R&D program for Bypass Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Vascular Bypass Market conversation — a $3.07B market you can size, segment and defend in minutes.
Market size · 2033$3.07Btotal opportunity
Growth5.3%CAGR to 2033
Addressable buyers1,265+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Bypass Type
Goal Grow share in Bypass Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 4 mopayback period
$57K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Medtronic plcTerumo CorporationW. L. Gore & Associates Inc.Getinge ABB. Braun Melsungen AGCook MedicalC.R. BardInc. (now part of BD)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Vascular Bypass Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Vascular Bypass Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Antioxidant Support Supplements Market
Market size, share, segmentation and regional forecast.
$675M market · 2025 base year
View reportVibrio Mimicus Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportPlesiomonas Shigelloides Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportAerosol Delivery Device Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportAntioxidant Pep-36 Market
Market size, share, segmentation and regional forecast.
$943M market · 2025 base year
View reportListeria Monocytogenes Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportVibrio Parahaemolyticus Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAntioxidant Nutritional Supplements Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportAstrovirus Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportClostridium Tetani Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportYersinia Pseudotuberculosis Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAeromonas Hydrophila Nucleic Acid Detection Kit Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.